Network-based identification of key proteins and repositioning of drugs for non-small cell lung cancer.
drug repurposing
drug–gene interaction
network analysis
non‐small cell lung cancer (NSCLC)
therapeutics
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
02
02
2024
received:
12
06
2023
accepted:
21
02
2024
medline:
11
4
2024
pubmed:
11
4
2024
entrez:
10
4
2024
Statut:
ppublish
Résumé
NSCLC is a lethal cancer that is highly prevalent and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment. This study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using a systems biology and network analysis approach. Differentially expressed genes in transcriptomics data were identified using the systems biology and network analysis approaches. A network of gene co-expression was developed with the aim of detecting two modules of gene co-expression. Following that, the Drug-Gene Interaction Database was used to find possible drugs that target important genes within two gene co-expression modules linked to non-small cell lung cancer (NSCLC). The use of Cytoscape facilitated the creation of a drug-gene interaction network. Finally, gene set enrichment analysis was done to validate candidate drugs. Unlike previous research on repositioning drugs for NSCLC, which uses a gene co-expression network, this project is the first to research both gene co-expression and co-occurrence networks. And the co-occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. For effective management of non-small cell lung cancer (NSCLC), drugs that show higher gene regulation and gene affinity within the drug-gene interaction network are thought to be important. According to the discourse, NSCLC genes have a lot of control over medicines like vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib. Hence, there is a possibility of repurposing these drugs for the treatment of non-small-cell lung cancer.
Sections du résumé
BACKGROUND
BACKGROUND
NSCLC is a lethal cancer that is highly prevalent and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment.
AIMS
OBJECTIVE
This study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using a systems biology and network analysis approach.
METHODS
METHODS
Differentially expressed genes in transcriptomics data were identified using the systems biology and network analysis approaches. A network of gene co-expression was developed with the aim of detecting two modules of gene co-expression. Following that, the Drug-Gene Interaction Database was used to find possible drugs that target important genes within two gene co-expression modules linked to non-small cell lung cancer (NSCLC). The use of Cytoscape facilitated the creation of a drug-gene interaction network. Finally, gene set enrichment analysis was done to validate candidate drugs.
RESULTS
RESULTS
Unlike previous research on repositioning drugs for NSCLC, which uses a gene co-expression network, this project is the first to research both gene co-expression and co-occurrence networks. And the co-occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. For effective management of non-small cell lung cancer (NSCLC), drugs that show higher gene regulation and gene affinity within the drug-gene interaction network are thought to be important. According to the discourse, NSCLC genes have a lot of control over medicines like vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib.
CONCLUSION
CONCLUSIONS
Hence, there is a possibility of repurposing these drugs for the treatment of non-small-cell lung cancer.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2031Informations de copyright
© 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7‐33. doi:10.3322/caac.21708
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics for 2020: GLOBOCAN estimates the incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249.
Zappa C, Mousa SA. Non‐small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288‐300.
Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. Lung Cancer: Treatment and Research. 2016:47‐75.
Kalinke L, Thakrar R, Janes SM. The promises and challenges of early non‐small cell lung cancer detection include patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers. Mol Oncol. 2021;15(10):2544‐2564.
Rajasegaran T, How CW, Saud A, Ali A, Lim JCW. Targeting inflammation in non‐small cell lung cancer through drug repurposing. Pharmaceuticals. 2023;16(3):451.
Wang L, Chen W, Xu X, et al. Effect of postoperative radiotherapy on survival in patients with completely resected and pathologically confirmed stage N2 non‐small‐cell lung cancer: a systematic review and meta‐analysis. Ther Adv Chronic Dis. 2023;14:20406223231195622.
Dongsar TT, Dongsar TS, Gupta N, Almalki WH, Sahebkar A, Kesharwani P. The emerging potential of 5‐fluorouracil‐loaded chitosan nanoparticles in cancer therapy. J Drug Deliv Sci Technol. 2023;82:104371.
Singh M, Kumar V, Sehrawat N, et al. Current paradigms in epigenetic anticancer therapeutics and future challenges. Semin Cancer Biol. 2022;83:422‐440.
Hua Y, Dai X, Xu Y, et al. Drug repositioning: progress and challenges in drug discovery for various diseases. Eur J Med Chem. 2022;234:114239.
Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41‐58.
Chen HR, Sherr DH, Hu Z, DeLisi C. A network‐based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med Genomics. 2016;9(1):1‐11.
Wang L, Wei CY, Xu YY, et al. Prognostic genes of melanoma were identified by weighted gene co‐expression network analysis and drug repositioning using a network‐based method. Oncol Lett. 2019;18(6):6066‐6078.
Boulos JC, Saeed ME, Chatterjee M, et al. Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells. Pharmaceuticals. 2021;14(11):1126.
MotieGhader H, Tabrizi‐Nezhadi P, Deldar Abad Paskeh M, et al. Drug repositioning in non‐small cell lung cancer (NSCLC) using gene co‐expression and drug‐gene interaction network analysis. Sci Rep. 2022;12(1):9417.
Wei TYW, Hsia JY, Chiu SC, et al. Methylosome protein 50 promotes androgen‐ and estrogen‐independent tumorigenesis. Cell Signal. 2014;26(12):2940‐2950.
Wei TYW, Juan CC, Hisa JY, et al. Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G 1 cyclins/cyclin‐dependent kinases and the phosphoinositide 3‐kinase/AKT signaling cascade. Cancer Sci. 2012;103(9):1640‐1650.
Lo FY, Chang JW, Chang I, et al. The database of chromosome imbalance regions and genes residing in lung cancer from Asian and Caucasian populations was identified by array‐comparative genomic hybridization. BMC Cancer. 2012;12(1):1‐13.
Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets update. Nucleic Acids Res. 2013;41(D1):D991‐D995. doi:10.1093/nar/gks1193
Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user‐uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605‐D612.
Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein‐protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638‐D646.
Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res. 2018;18(2):623‐632.
Zhou H, Liu J, Li J, Duan W. A density‐based approach for detecting complexes in weighted PPI networks by semantic similarity. PloS One. 2017;12(7):e0180570.
Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist‐oriented resource for the analysis of systems‐level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467‐019‐09234‐6
Tripathi S, Pohl MO, Zhou Y, et al. Meta‐and orthogonal integration of influenza “OMICs” data defines a role for UBR4 in virus budding. Cell Host Microbe. 2015;18(6):723‐735.
Cotto KC, Wagner AH, Feng YY, et al. DGIdb 3.0: a redesign and expansion of the drug‐gene interaction database. Nucleic Acids Res. 2018;46(D1):D1068‐D1073.
Powers RK, Goodspeed A, Pielke‐Lombardo H, Tan AC, Costello JC. GSEA‐InContext: identifying novel and common patterns in expression experiments. Bioinformatics. 2018;34(13):i555‐i564.
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein‐protein association networks with increased coverage, supporting functional discovery in genome‐wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607‐D613.
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498‐2504.
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353‐D361.
Gillespie M, Jassal B, Stephan R, et al. The reactome pathway knowledge base 2022. Nucleic Acids Res. 2022;50(D1):D687‐D692.
Tsitsiridis G, Steinkamp R, Giurgiu M, et al. CORUM: the comprehensive resource of mammalian protein complexes–2022. Nucleic Acids Res. 2023;51(D1):D539‐D545.
Mi H, Thomas P. PANTHER pathway: An ontology‐based pathway database coupled with data analysis tools. Methods Mol Biol. 2009;123‐140.
Martens M, Ammar A, Riutta A, et al. WikiPathways: connecting communities. Nucleic Acids Res. 2021;49(D1):D613‐D621.
Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 2007;36(suppl_1):D684‐D688.
Liu H, Yuan M, Mitra R, et al. CTpathway: a cross‐talk‐based pathway enrichment analysis method for cancer research. Genome Med. 2022;14(1):118. doi:10.1186/s13073‐022‐01119‐6
Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2021;23:74‐88. doi:10.1038/s41580‐021‐00404‐3
Martins Cavaco AC, Dâmaso S, Casimiro S, Costa L. Collagen biology is making inroads into the prognosis and treatment of cancer progression and metastasis. Cancer Metast Rev. 2020;39(3):603‐623. doi:10.1007/s10555‐020‐09888‐5
Li LY, Guan YD, Chen XS, Yang JM, Cheng Y. DNA repair pathways in cancer therapy and resistance. Front Pharmacol. 2021;11:629266. doi:10.3389/fphar.2020.629266
Kou F, Sun H, Wu L, et al. TOP2A promotes lung adenocarcinoma cells' malignant progression and predicts poor prognosis in lung adenocarcinoma. J Cancer. 2020;11(9):2496‐2508.
Matias‐Barrios VM, Dong X. The implication of topoisomerase II inhibitors in synthetic lethality for cancer therapy. Pharmaceuticals (Basel, Switzerland). 2023;16(1):94. doi:10.3390/ph16010094
Kotoula V, Krikelis D, Karavasilis V, et al. Expression of DNA repair and replication genes in non‐small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). BMC Cancer. 2012;12:342. doi:10.1186/1471‐2407‐12‐342
Hernández‐Pérez S, Cabrera E, Salido E, et al. The replication inhibitor geminin is controlled by DUB3 and USP7 de‐ubiquitinating enzymes. This study looks at Geminin's molecular structure and how it is linked to breast cancer. Oncogene. 2017;36(33):480‐4809. doi:10.1038/onc.2017.21 Erratum in: Oncogene. 2017 Jun 26; Erratum in: Oncogene. 2019 Jun;38(24):4886. PMID: 28288134.
Frazzi R. BIRC3 and BIRC5: multifaceted inhibitors in cancer. Cell Biosci. 2021;11(1):1‐4. doi:10.1186/s13578‐020‐00521‐0
Qian X, Song X, He Y, et al. CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients. Biomed Pharmacother. 2015;74:222‐227. doi:10.1016/j.biopha.2015.08.004
Yu J, Zhou J, Xu F, Bai W, Zhang W. High expression of Aurora‐B is correlated with poor prognosis and drug resistance in non‐small‐cell lung cancer. Int J Biol Markers. 2018;33(2):215‐221. doi:10.1177/1724600817753098
Dhyani P, Quispe C, Sharma E, et al. Anticancer potential of alkaloids: a key emphasis on colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int. 2022;22(1):1‐20.
Ghosh S, Lalani R, Maiti K, et al. Synergistic co‐loading of vincristine improved the chemotherapeutic potential of pegylated liposomal doxorubicin against triple‐negative breast cancer and non‐small‐cell lung cancer. Nanomed Nanotechnol Biol Med. 2021;31:102320.
Ghosh S, Lalani R, Maiti K, et al. Optimization and efficacy study of synergistic vincristine‐coloaded liposomal doxorubicin against breast and lung cancer. Nanomedicine. 2020;15(26):2585‐2607.
Kumar N, Salar RK, Prasad M, Ranjan K. Synthesis, characterization and anticancer activity of vincristine‐loaded folic acid‐chitosan‐conjugated nanoparticles on the NCI‐H460 non‐small cell lung cancer cell line. Egypt J Basic Appl Sci. 2018;5(1):87‐99.
Sampson J, Ju HM, Song JY, Fry AM, Bayliss R, Choi J. A polytherapy strategy using vincristine and ALK inhibitors to sensitize EML4‐ALK‐positive NSCLC. Cancer. 2022;14(3):779.
Martino E, Casamassima G, Castiglione S, et al. Vinca alkaloids and analogues as anti‐cancer agents: looking back and peering ahead. Bioorg Medi Chem Lett. 2018;28(17):2816‐2826.
Dhumad AM, Majeed HJ, Zandi H, Harismah K. FeC19 cage vehicle for fluorouracil anticancer drug delivery: DFT approach. J Mol Liq. 2021;333:115905.
Wang H, Yang T, Wu X. 5‐Fluorouracil preferentially sensitizes mutant KRAS non‐small cell lung carcinoma cells to TRAIL‐induced apoptosis. Mol Oncol. 2015;9(9):1815‐1824.
Subaiea G, Rizvi SMD, Yadav HKS, et al. The combination of ganetespib and methotrexate works together to stop NF‐κB/p65 signaling in human lung cancer A549 cells. Pharmaceuticals. 2023;16(2):230.
Weng N, Zhang Z, Tan Y, Zhang X, Wei X, Zhu Q. Repurposing antifungal drugs for cancer therapy. J Adv Res. 2023;48:259‐273.
Sebastian N, Stokes WA, Behera M, et al. Association of azole antifungals with survival in patients with non‐small cell lung cancer receiving immunotherapy. J Clin Oncol. 2021;39:e18777.
Ferguson DM, Jacobson BA, Jay‐Dixon J, Patel MR, Kratzke RA, Raza A. Targeting topoisomerase II activity in NSCLC with 9‐aminoacridine derivatives. Anticancer Res. 2015;35(10):5211‐5217.
Peng J, Sengupta S, Jordan VC. Potential of selective estrogen receptor modulators as treatments and preventives for breast cancer. Anticancer Agents Med Chem. 2009;9(5):481‐499. doi:10.2174/187152009788451833
Gil M, Iyer R, Opyrchal M, Weroha SJ. Multi‐targeted kinase inhibitor sorafenib and its future. Cancer Chemother Rev. 2015;10(1):16‐24.
Van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 2021;288(21):6095‐6111.
Tullemans BME, Nagy M, Sabrkhany S, et al. Tyrosine kinase inhibitor pazopanib inhibits platelet procoagulant activity in renal cell carcinoma patients. Front Cardiovasc Med. 2018;5:142. doi:10.3389/fcvm.2018.00142